Soluble tumor necrosis factor receptors (sTNFR) are the cleaved-off extracellular domains of transmembrane TNF receptors. They are proposed to enter the bloodstream either via shedding by the enzyme TACE or through exocytosis of the full-length receptor in exosome-like vesicles. Elevated levels of sTNFR are seen in inflammatory processes such as infection, malignancy and autoimmune diseases.[1]
References
|
---|
Chemokine | |
---|
CSF | |
---|
Interferon | IFNAR (α/β, I) |
- Agonists: Albinterferon
- Interferon alpha (interferon alfa, IFN-α)
- Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)
- Interferon alfa 2a
- Interferon alfa 2b
- Interferon alfa n1
- Interferon alfacon-1
- Interferon alpha-n3
- Interferon beta (IFN-β) (IFNB1, IFNB3)
- Interferon beta 1a
- Interferon beta 1b
- Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
- Interferon omega (IFN-ω, IFNW1)
- Peginterferon alfa-2a
- Peginterferon alfa-2b
- Antibodies: Anifrolumab
- Faralimomab
- MEDI-545
- Rontalizumab
- Sifalimumab
- Decoy receptors: Bifarcept
|
---|
IFNGR (γ, II) |
- Antibodies: Emapalumab
- Fontolizumab
|
---|
IFNLR (λ, III) |
- See IL-28R (IFNLR) here instead.
|
---|
|
---|
Interleukin | |
---|
TGFβ | |
---|
TNF | |
---|
Others | JAK (inhibitors) | JAK1 |
- Abrocitinib
- Baricitinib
- Deuruxolitinib
- Filgotinib
- Momelotinib
- Oclacitinib
- Peficitinib
- Ruxolitinib
- Tofacitinib (tasocitinib)
- Upadacitinib
|
---|
JAK2 |
- Atiprimod
- AZD-1480
- Baricitinib
- CHZ868
- Cucurbitacin I (elatericin B, JSI-124)
- CYT387
- Deuruxolitinib
- Lestaurtinib
- NSC-7908
- NSC-33994
- Pacritinib
- Peficitinib
- Ruxolitinib
- SD-1008
- Tofacitinib (tasocitinib)
|
---|
JAK3 |
- Cercosporamide
- Decernotinib (VX-509)
- Peficitinib
- Ritlecitinib
- TCS-21311
- Tofacitinib (tasocitinib)
- WHI-P 154
- ZM-39923
- ZM-449829
|
---|
TYK2 | |
---|
|
---|
Others |
- Additional cytokine receptor modulators: Emfilermin
- Lestaurtinib
- Midostaurin
- Quizartinib
- Sorafenib
- Sunitinib
|
---|
|
---|